Literature DB >> 22506137

Ovarian Cancer Is an Imported Disease: Fact or Fiction?

Elisabetta Kuhn1, Robert J Kurman, Ie-Ming Shih.   

Abstract

The cell of origin of ovarian cancer has been long debated. The current paradigm is that epithelial ovarian cancer (EOC) arises from the ovarian surface epithelium (OSE). OSE is composed of flat, nondescript cells more closely resembling the mesothelium lining the peritoneal cavity, with which it is continuous, rather than the various histologic types of ovarian carcinoma (serous, endometrioid, and clear cell carcinoma), which have a Müllerian phenotype. Accordingly, it has been argued that the OSE undergoes a process termed "metaplasia" to account for this profound morphologic transformation. Recent molecular and clinicopathologic studies not only have failed to support this hypothesis but also have provided evidence that EOC stems from Müllerian-derived extraovarian cells that involve the ovary secondarily, thereby calling into question the very existence of primary EOC. This new model of ovarian carcinogenesis proposes that fallopian tube epithelium (benign or malignant) implants on the ovary to give rise to both high-grade and low-grade serous carcinomas, and that endometrial tissue implants on the ovary and produces endometriosis, which can undergo malignant transformation into endometrioid and clear cell carcinoma. Thus, ultimately EOC is not ovarian in origin but rather is secondary, and it is logical to conclude that the only true primary ovarian neoplasms are germ cell and gonadal stromal tumors analogous to tumors in the testis. If this new model is confirmed, it has profound implications for the early detection and treatment of "ovarian cancer."

Entities:  

Year:  2012        PMID: 22506137      PMCID: PMC3322388          DOI: 10.1007/s13669-011-0004-1

Source DB:  PubMed          Journal:  Curr Obstet Gynecol Rep        ISSN: 2161-3303


  68 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.

Authors:  R R Barakat; M G Federici; P E Saigo; M E Robson; K Offit; J Boyd
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

3.  The tubal hypothesis of ovarian cancer: caution needed.

Authors:  Ian M Collins; Susan M Domchek; David G Huntsman; Gillian Mitchell
Journal:  Lancet Oncol       Date:  2011-08-23       Impact factor: 41.316

4.  Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis.

Authors:  M E Sherman; J S Lee; R T Burks; J P Struewing; R J Kurman; P Hartge
Journal:  Int J Gynecol Pathol       Date:  1999-04       Impact factor: 2.762

5.  Ovarian dysplasia in epithelial inclusion cysts. A morphometric approach using neural networks.

Authors:  L Deligdisch; A J Einstein; D Guera; J Gil
Journal:  Cancer       Date:  1995-09-15       Impact factor: 6.860

6.  DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma.

Authors:  Kuan-Ting Kuo; Tsui-Lien Mao; Xu Chen; Yuanjian Feng; Kentaro Nakayama; Yue Wang; Ruth Glas; M Joe Ma; Robert J Kurman; Ie-Ming Shih; Tian-Li Wang
Journal:  Clin Cancer Res       Date:  2010-03-16       Impact factor: 12.531

7.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

8.  Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer.

Authors:  Ann K Folkins; Aasia Saleemuddin; Leslie A Garrett; Judy E Garber; Michael G Muto; Shelley S Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2009-07-16       Impact factor: 5.482

9.  Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention.

Authors:  William J Murdoch; James F Martinchick
Journal:  Exp Biol Med (Maywood)       Date:  2004-06

10.  Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.

Authors:  Siân Jones; Meng Li; D Williams Parsons; Xiaosong Zhang; Jelle Wesseling; Petra Kristel; Marjanka K Schmidt; Sanford Markowitz; Hai Yan; Darell Bigner; Ralph H Hruban; James R Eshleman; Christine A Iacobuzio-Donahue; Michael Goggins; Anirban Maitra; Sami N Malek; Steve Powell; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Hum Mutat       Date:  2011-11-23       Impact factor: 4.878

View more
  36 in total

1.  The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma.

Authors:  Elisabetta Kuhn; Robert J Kurman; Robert A Soslow; Guangming Han; Ann Smith Sehdev; Patrick J Morin; Tian-Li Wang; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

Review 2.  Ovarian Cancer Prevention in High-risk Women.

Authors:  Sarah M Temkin; Jennifer Bergstrom; Goli Samimi; Lori Minasian
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

3.  Method for obtaining primary ovarian cancer cells from solid specimens.

Authors:  Lee J Pribyl; Kathleen A Coughlin; Thanasak Sueblinvong; Kristin Shields; Yoshie Iizuka; Levi S Downs; Rahel G Ghebre; Martina Bazzaro
Journal:  J Vis Exp       Date:  2014-02-04       Impact factor: 1.355

4.  Ultraminiature optical design for multispectral fluorescence imaging endoscopes.

Authors:  Tyler H Tate; Molly Keenan; John Black; Urs Utzinger; Jennifer K Barton
Journal:  J Biomed Opt       Date:  2017-03-01       Impact factor: 3.170

5.  TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target.

Authors:  Lin-Yu Chen; Rui-Lan Huang; Michael Wy Chan; Pearlly S Yan; Tien-Shuo Huang; Ren-Chin Wu; Yohan Suryo Rahmanto; Po-Hsuan Su; Yu-Chun Weng; Jian-Liang Chou; Tai-Kuang Chao; Yu-Chi Wang; Ie-Ming Shih; Hung-Cheng Lai
Journal:  J Pathol       Date:  2019-04-23       Impact factor: 7.996

6.  Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer.

Authors:  Shiho Asaka; Christine Davis; Shiou-Fu Lin; Tian-Li Wang; Christopher M Heaphy; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2019-08       Impact factor: 6.394

Review 7.  The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Authors:  Anthony N Karnezis; Kathleen R Cho; C Blake Gilks; Celeste Leigh Pearce; David G Huntsman
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

8.  Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.

Authors:  Yusuke Kobayashi; Hiroyasu Kashima; Ren-Chin Wu; Jin-Gyoung Jung; Jen-Chun Kuan; Jinghua Gu; Jianhua Xuan; Lori Sokoll; Kala Visvanathan; Ie-Ming Shih; Tian-Li Wang
Journal:  Clin Cancer Res       Date:  2015-06-24       Impact factor: 12.531

Review 9.  Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.

Authors:  Daichi Maeda; Ie-Ming Shih
Journal:  Adv Anat Pathol       Date:  2013-01       Impact factor: 3.875

10.  Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.

Authors:  Tarrik M Zaid; Tsz-Lun Yeung; Melissa S Thompson; Cecilia S Leung; Tom Harding; Ngai-Na Co; Rosie S Schmandt; Suet-Ying Kwan; Cristian Rodriguez-Aguay; Gabriel Lopez-Berestein; Anil K Sood; Kwong-Kwok Wong; Michael J Birrer; Samuel C Mok
Journal:  Clin Cancer Res       Date:  2013-01-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.